Project Grant R01CA304441
Award Date 8/1/25
Completion Date 7/31/29
Dollars Obligated $3.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- The Sloan-Kettering Institute for Cancer Research was awarded a $581,381 Project Grant by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance. The project aims to gain a better understanding of DNA damage repair pathways and how they go awry in cancer, with the goal of informing more effective therapeutic approaches. Specifically, the research will...
- This $238,722 federal Project Grant awarded on August 18, 2025 by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the Sloan-Kettering Institute for Cancer Research supports research to investigate the role of mutagenic DNA repair during the persistence of cancer cells. The research aims to define the specific mechanisms that promote mutagenic DNA repair and drive acquired drug resistance in persister cancer cells, focusing on the role of the microhomology-mediated end...
- This $292,028 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms by which oncogene amplification leads to genome instability and the development of therapy-resistant cancer clones. The research will be conducted by the Sloan-Kettering Institute for Cancer Research in New York and is scheduled to run from August 1, 2025 to July 31, 2030. Using single-cell genomic sequencing techniques, the project aims...
- The National Cancer Institute (NCI) awarded a $487,393 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research in New York, NY, effective December 1, 2024 through November 30, 2029. The grant supports research to determine the role of RAD52, HELQ, and POLQ proteins in backup DNA double-strand break repair pathways, which are critical for the survival of homologous recombination deficient (HRD) cancer cells. The research aims to...
- This $1,449,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports research to study the fundamental regulation of extrachromosomal DNA (ecDNA) in cancer genomes. The project aims to develop new live-cell chromatin labeling strategies and integrate advanced imaging, synthetic genome engineering, and optical/genetic perturbation to systematically investigate how ecDNA orchestrates massive...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research by the Stowers Institute for Medical Research to investigate the impact of natural variation in human centromeric DNA sequences and epigenetic patterns on chromosome segregation and genome integrity. The $125,619 grant, awarded on August 1, 2025, will fund research over a 5-year period to map centromeric DNA landscapes and associated kinetochore proteins...
- The National Cancer Institute (NCI) awarded a $1,034,176 Project Grant to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) with an award date of August 18, 2025. The grant aims to understand the mechanisms of aberrant RNA splicing and how it drives the development of various hematological malignancies, including myelodysplastic syndrome, chronic lymphocytic leukemia, and acute myeloid leukemia. The research builds on the institution's past...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $1,625,853 Project Grant to New York University (NYU) on December 13, 2024. The grant will support NYU's research to map and characterize the role of 3D "hubs" - regulatory DNA elements that interact with multiple loci - in the context of T-cell leukemia (T-ALL), early T-cell progenitor leukemia (ETP-ALL), and T-cell lymphoma. The project aims to better define how these 3D chromatin structures are rewired...
- The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
- This federal Project Grant award of $418,176 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development and validation of a novel approach called "Programmable Nucleic Acid Cytometry" at the Sloan-Kettering Institute for Cancer Research. The project aims to advance this innovative method for profiling rare cell populations from tumors and tissues, which offers advantages over traditional antibody-based cell isolation techniques. The work will...